AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 111 min read$AXSM

Coleman Mark sold $160K of AXSM

Coleman Mark sold 643 shares of Axsome Therapeutics, Inc. (AXSM) at $249.00 ($0.16M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coleman Mark
Published Jun 11, 2026, 1:49 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AXSM
Neutral
high confidence
Mentioned
$AXSM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXSMNeutralLow
01

Why it matters

A director’s open-market sale under a 10b5-1 plan is generally considered lower-signal than discretionary selling, so the market impact is typically limited.

02

Market read

Primarily a sentiment datapoint; not a new fundamental development for AXSM.

03

What to watch

Watch for follow-on insider activity (additional sales/buys) or any concurrent company-specific news; a single small sale often has limited predictive value.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10 (transaction dated 2026-06-10)

Background

The article reports an SEC Form 4 insider transaction for Axsome Therapeutics, Inc. (AXSM).

Company-level read

Ticker impact

$AXSMNeutralHigh confidence
Context

Director Coleman Mark sold 643 shares of Axsome Therapeutics on 2026-06-10 at $249/share under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear read-across to the broader biotech sector from a single director 10b5-1 sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is pre-arranged, it may reflect scheduled liquidity rather than bearish views; traders may ignore it unless paired with other negative catalysts.

Key entities

  • issuer
    Axsome Therapeutics, Inc.

    Subject of the Form 4 insider transaction (AXSM).

  • insider
    Coleman Mark

    Director who sold 643 shares on 2026-06-10 under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AXSM insider trading history →

Related articles

AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min
AUG 11
$AXSMMed

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.

yahoo.com6 min